Literature DB >> 8474265

Urolithiasis in pediatric patients.

D S Milliner1, M E Murphy.   

Abstract

Urolithiasis in pediatric patients has been perceived as uncommon, and the appropriate evaluation and management have been controversial. To determine the clinical characteristics, types of stone problems, and outcomes of pediatric patients with urolithiasis encountered in a referral center, we retrospectively assessed 221 patients (113 girls and 108 boys) with urolithiasis examined at the Mayo Clinic between 1965 and 1987. The median age at onset of symptoms was 11 6/12 years among the female patients and 10 6/12 years among the male patients. Analysis of stone constituents in 122 patients showed the proportion of calcium oxalate (44.7%), calcium phosphate (23.6%), and cystine (8.1%) stones to be similar in all age-groups. Overall, struvite stones were found in 17.1% and uric acid stones in 1.6% of patients. Conditions that predisposed to metabolic urolithiasis were identified in 115 patients (52%). Hypercalciuria was confirmed in 49 of 145 patients (33.8%) and hyperoxaluria in 25 of 124 (20.2%). Eight of 96 patients had hyperuricosuria, and 5 of 54 had hypocitraturia. Forty-one patients (18.6%) had infection-related stones. Of 66 patients with structural anomalies of the genitourinary tract, 24 (36%) had metabolic abnormalities and 26 (39%) had chronic infection. Among patients with chronic infection, 29% had metabolic abnormalities. Of the 221 patients, 148 (67%) had two or more stones during a mean follow-up of 59 months. Among 140 patients with 12 months or more of follow-up, metabolic activity was present in 31 (22.1%) at the time of most recent examination. Overall, 166 of 221 children (75.1%) were found to have factors that predisposed to urolithiasis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8474265     DOI: 10.1016/s0025-6196(12)60043-3

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  73 in total

Review 1.  Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Authors:  Michael H Lee; Amrik Sahota; Michael D Ward; David S Goldfarb
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 2.  Pediatric urolithiasis: causative factors, diagnosis and medical management.

Authors:  Funda Baştuğ; Ruhan Düşünsel
Journal:  Nat Rev Urol       Date:  2012-02-07       Impact factor: 14.432

Review 3.  Pediatric urolithiasis: etiology, specific pathogenesis and medical treatment.

Authors:  K Sarica
Journal:  Urol Res       Date:  2006-01-24

4.  Case 2: An unusual cause of urinary symptoms.

Authors:  Kate M Young; Chad Newell; Jack Lazerson
Journal:  Paediatr Child Health       Date:  2007-12       Impact factor: 2.253

5.  Bilateral ureter stones in a 1-year-old boy.

Authors:  Hyewon Hahn; Jeongyoon Kang; Curie Kim
Journal:  Pediatr Nephrol       Date:  2009-04-07       Impact factor: 3.714

Review 6.  Ureteroscopy for treatment of upper urinary tract stones in children: technical considerations.

Authors:  Natasha Gupta; Joan Ko; Brian R Matlaga; Ming-Hsien Wang
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

7.  Role of urinary supersaturation in the evaluation of children with urolithiasis.

Authors:  Marc B Lande; William Varade; Elif Erkan; Yvonne Niederbracht; George J Schwartz
Journal:  Pediatr Nephrol       Date:  2005-02-17       Impact factor: 3.714

8.  Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2015-09-06

Review 9.  Pediatric stone disease.

Authors:  Stacy T Tanaka; John C Pope
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

10.  Clinical and metabolic features of urolithiasis and microlithiasis in children.

Authors:  Harika Alpay; Ahmet Ozen; Ibrahim Gokce; Nese Biyikli
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.